• Attribution:

  • Kim E Gefinitib versus vinorelbine-cisplatin as adjuvant treatment in NSCLC.

  • In stage II-IIIA NSCLC with EGFR-activating mutation

  • https://www.youtube.com/watch?v=0MpwA2kY66k (6/2017)

  • OBRoncology Youtube Channel:  https://www.youtube.com/channel/UCn_dOPbmzqeL7glzj1yM1ug

Previous Video

Next Video